Vivo Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Vivo Capital’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-934,879	Closed	-$35.9M	–	55
2023 Q2	$35.9M	Buy	934,879 +62,728	+7%	+$1.61M	2.48%	10
2023 Q1	$20.2M	Hold	872,151	–	–	1.4%	13
2022 Q4	$22.9M	Hold	872,151	–	–	2.63%	14
2022 Q3	$17.1M	Hold	872,151	–	–	1.89%	16
2022 Q2	$15.3M	Hold	872,151	–	–	1.53%	13
2022 Q1	$14.3M	Hold	872,151	–	–	0.98%	24
2021 Q4	$14.2M	Hold	872,151	–	–	0.86%	27
2021 Q3	$11.1M	Hold	872,151	–	–	0.5%	34
2021 Q2	$12.3M	Sell	872,151 -334,115	-28%	-$5.34M	0.53%	34
2021 Q1	$18.7M	Hold	1,206,266	–	–	0.66%	31
2020 Q4	$19.1M	Buy	1,206,266 +182,554	+18%	+$2.75M	0.85%	27
2020 Q3	$12.4M	Hold	1,023,712	–	–	0.72%	37
2020 Q2	$11.8M	Hold	1,023,712	–	–	0.85%	30
2020 Q1	$14M	Buy	+1,023,712	New	+$12.1M	1.27%	23

Vivo Capital's KDNY Position: Q3 2023 in Review

Vivo Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 934,879 shares — an estimated $35.9M sold.

Vivo Capital first reported a position in KDNY in Q1 2020 and held it in 14 quarters. The position peaked at $35.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Vivo Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Vivo Capital sold 934,879 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $35.9M.
Vivo Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2020 and held it in 14 quarters.
Vivo Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $35.9M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Vivo Capital's 13F filing for Q3 2023, filed 8 Nov 2023.